drugset
drugset / Trial / NCT01925521

OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects.

NCT01925521 ↗

Phase 1 Completed 96 enrolled Korea Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The objective of this trial is to evaluate the safety and tolerability of single and multiple ascending oral doses of OPS-2071 in healthy male Korean

Timeline

Start
2013-08
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject OPS-2071 Small molecule 30 mg Oral
Subject OPS-2071 Small molecule 60 mg Oral
Subject OPS-2071 Small molecule 120 mg Oral
Subject OPS-2071 Small molecule 240 mg Oral
Subject OPS-2071 Small molecule 300 mg Oral
Subject OPS-2071 Small molecule 600 mg Oral
Subject OPS-2071 Small molecule 900 mg Oral
Subject OPS-2071 Small molecule 1200 mg Oral

Indications

No indication recorded.